OUP user menu

Journal of Crohn's and Colitis: 9 (4)

Editor-in-Chief

Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium

3.562
4.023

Published on behalf of

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis

Kristian Thorlund , Eric Druyts , Edward J. Mills , Richard N. Fedorak , John K. Marshall
DOI: http://dx.doi.org/10.1016/j.crohns.2014.01.010 571-581 First published online: 1 July 2014

Abstract

Objective To compare the efficacy of adalimumab and infliximab for the treatment of moderate to severe ulcerative colitis using indirect treatment comparison meta-analysis.

Methods A systematic review and Bayesian indirect treatment comparison meta-analyses were performed for seven patient-important clinical outcomes at 8 weeks and 52 weeks. Odds ratio (OR) estimates and associated 95% credible intervals (CrIs) were produced.

Results Five eligible RCTs informed clinical remission, response, mucosal healing, quality of life, colectomy, serious adverse events, and discontinuation due to adverse events at 8 weeks and 52 weeks. At 8 weeks of induction therapy, clinical remission (OR = 0.42, 95% CrI 0.17–0.97), clinical response (OR = 0.45, 95% CrI 0.23–0.89) and mucosal healing (OR = 0.46, 95% CrI 0.25–0.86) statistically favored infliximab. However, after 52 weeks of maintenance therapy OR estimates showed no significant difference between infliximab and adalimumab. For serious adverse events and discontinuations due to adverse events, adalimumab and infliximab were similar to placebo. Further, the indirect treatment comparison of adalimumab and infliximab yielded odds ratios close to 1.00 with wide credible intervals.

Keywords
  • Anti-TNF
  • Ulcerative colitis
  • Indirect treatment comparison
  • Meta-analysis
  • Adalimumab
  • Infliximab
View Full Text

Dear ECCO Member

You now have access to JCC (Journal of Crohn’s and Colitis) and its Supplements as part of your ECCO Membership. Enjoy!
In case you wish to set up table of contents alerts (eToCs), latest article alerts (Advance Access alerts) or other search alerts, you will need to register for an Oxford Journals MyAccount here.

Log in through your institution